NAUT
Nautilus Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.97
−0.59%Sep 11, 2026, 20:14 UTC
Nautilus Biotechnology, Inc. mutually terminated its prior at-the-market equity offering program with TD Securities (USA), LLC as sales agent.
Sep 11, 2026, 20:14 UTC
Nautilus Biotechnology, Inc. entered into a sales agreement to sell up to $125,000,000 of common stock through an at-the-market offering program, with TD Securities (USA), LLC acting as sales agent.
Jul 28, 2026, 00:00 UTC
Nautilus Biotechnology reported Q2 2026 financial results with total revenue of $0.2 million and a net loss of $14.5 million.